Earnings summaries and quarterly performance for VERTEX PHARMACEUTICALS INC / MA.
Executive leadership at VERTEX PHARMACEUTICALS INC / MA.
Reshma Kewalramani
Detailed
Chief Executive Officer and President
CEO
JL
Jeffrey Leiden
Detailed
Executive Chairman
CW
Charles Wagner
Chief Financial Officer and Chief Operating Officer
DA
David Altshuler
Executive Vice President and Chief Scientific Officer
DM
Duncan McKechnie
Chief Commercial Officer
JB
Jonathan Biller
Executive Vice President, Chief Legal Officer
Board of directors at VERTEX PHARMACEUTICALS INC / MA.
AG
Alan Garber
Detailed
Director
BS
Bruce Sachs
Detailed
Lead Independent Director
DM
Diana McKenzie
Detailed
Director
JS
Jennifer Schneider
Detailed
Director
LC
Lloyd Carney
Detailed
Director
ML
Michel Lagarde
Detailed
Director
NT
Nancy Thornberry
Detailed
Director
SB
Sangeeta Bhatia
Detailed
Director
SU
Suketu Upadhyay
Detailed
Director
Research analysts who have asked questions during VERTEX PHARMACEUTICALS INC / MA earnings calls.
ES
Evan Seigerman
BMO Capital Markets
4 questions for VRTX
Also covers: ABBV, AMGN, ARVN +15 more
JF
Jessica Fye
JPMorgan Chase & Co.
4 questions for VRTX
Also covers: ALKS, ALNY, AMRN +23 more
Salveen Richter
Goldman Sachs
4 questions for VRTX
Also covers: ACAD, AGIO, ALLO +20 more
TA
Tazeen Ahmad
Bank of America
4 questions for VRTX
Also covers: ACAD, ALNY, APLS +21 more
DR
David Risinger
Leerink Partners
3 questions for VRTX
Also covers: ABBV, AMGN, BMY +9 more
Liisa Bayko
Evercore ISI
3 questions for VRTX
Also covers: ALT, BCRX, INSM +7 more
Michael Yee
Jefferies
3 questions for VRTX
Also covers: ALLO, AMGN, BEAM +14 more
EM
Eliana Merle
UBS
2 questions for VRTX
Also covers: ALNY, APLS, ARVN +17 more
Geoffrey Meacham
Citi
2 questions for VRTX
Also covers: ABBV, BIIB, BMY +6 more
Mohit Bansal
Wells Fargo & Company
2 questions for VRTX
Also covers: ABBV, AMGN, BMRN +16 more
OB
Olivia Brayer
Cantor
2 questions for VRTX
Also covers: AMGN, AUPH, BMRN +8 more
PN
Philip Nadeau
TD Cowen
2 questions for VRTX
Also covers: ADVM, APLS, ATRA +13 more
WP
William Pickering
Sanford C. Bernstein & Co.
2 questions for VRTX
Also covers: ALLO, ARWR, NTLA +1 more
C
Chris
Morgan Stanley
1 question for VRTX
Also covers: GILD, MRNA, REGN
DC
Debjit Chattopadhyay
Guggenheim Securities
1 question for VRTX
Also covers: BEAM, BOLD, HOOK +5 more
DR
Divya Rao
TD Cowen
1 question for VRTX
Also covers: AGIO, APLS, PBYI +1 more
EM
Ellie Merle
UBS Group AG
1 question for VRTX
Also covers: ALNY, ALT, ARVN +12 more
Geoff Meacham
Citigroup Inc.
1 question for VRTX
Also covers: ABBV, AMGN, BMY +8 more
HW
Huidong Wang
Barclays
1 question for VRTX
Also covers: ALNY, BCRX, BEAM +15 more
Terence Flynn
Morgan Stanley
1 question for VRTX
Also covers: ABBV, AMGN, ARVN +17 more
Recent press releases and 8-K filings for VRTX.
Vertex outlines 2026 commercial and pipeline priorities at JPM Healthcare Conference
VRTX
Product Launch
Guidance Update
New Projects/Investments
- Vertex plans to sustain CF leadership into 2037 and beyond, driven by the global roll-out of Vanzacaftor and continued Trikafta/Kaftrio launches, leveraging 95% patient eligibility and modelled survival into the 80s with early treatment.
- Casgevy reached over $100 million in 2025 revenues, with filings for 5–11-year-olds planned in 2026 under the priority review voucher, as Vertex targets multi-billion-dollar potential across the U.S., Europe and Middle East.
- Jurnavix, launched in January 2025 for moderate-to-severe acute pain, amassed 500,000 prescriptions by year-end, saw Q4 scripts grow 50% sequentially, and aims to triple prescriptions in 2026 by doubling its field force and expanding payer coverage to two-thirds of Americans.
- The Povy (povetacicept) IgAN submission is underway under Breakthrough designation, targeting accelerated U.S. approval in H1 2026; the monthly, 0.46 mL auto-injector is positioned for best-in-class efficacy, safety and patient adherence.
- Vertex’s emerging renal franchise now encompasses four mid-/late-stage programs (IgAN, AMKD, ADPKD, APOL1), with APOL1 interim data expected late 2026 and potential accelerated filing thereafter.
Jan 12, 2026, 10:15 PM
Vertex outlines 2026 strategy at 44th Annual J.P. Morgan Healthcare Conference
VRTX
Product Launch
New Projects/Investments
- Vertex projects sustained CF portfolio growth via the ALYFTREK launch, expansion into younger patients and patent protection through ~2040.
- CASGEVY exceeded $100 M in FY 2025 revenues, with 301 patients initiated and over 60 cell infusions, targeting multi-billion dollar potential.
- Acute pain launch JOURNAVX achieved >500 K prescriptions and covers >200 M lives; Vertex plans to double its field team and target >3× prescriptions in 2026.
- Renal franchise advancing: BLA submission for povetacicept in IgAN expected H1 2026 and Phase 3 interim results for inaxaplin in late 2026/early 2027.
- 2026 guidance calls for $11.9–12 B in total revenue, S&M to rise to ~35% of OpEx, and ~$12 B cash on hand to fuel innovation.
Jan 12, 2026, 10:15 PM
Vertex outlines 2026 commercialization priorities and pipeline progress
VRTX
Product Launch
Guidance Update
- Vertex’s 2026 commercialization priorities are to sustain CF market leadership (Trikafta IP through 2037), drive Casgevy toward blockbuster status after finishing 2025 with >$100 million in revenue, triple Jurnavix prescriptions, and prepare for Povy launch in IgAN.
- Casgevy in sickle cell disease and β-thalassemia saw Best-in-ASH recognition for 5–11 year-old data, with a filing planned this year and a multi-billion-dollar market opportunity across the US, Europe, and Middle East.
- Jurnavix achieved >500,000 scripts in 2025 (50% Q4 vs Q3 growth), secured formulary coverage with all three major PBMs (~66% of adults), and plans to 3× its scripts in 2026 by expanding its salesforce from 150 to 300 reps.
- The emerging renal franchise’s lead asset, Povetacicept (Povy), is engineered as a monthly, 0.46 mL auto-injector dual BAFF-APRIL inhibitor, poised for phase III interim analysis and potential accelerated approval in IgAN.
- Financially, Vertex reaffirmed 2025 revenue guidance of $11.9–12.0 billion, targets two-thirds of operating expenditure to R&D, and aims to deliver five launches in five disease areas over five years.
Jan 12, 2026, 10:15 PM
Vertex outlines 2026 commercial priorities and pipeline progress
VRTX
Product Launch
Guidance Update
- Vertex’s 2026 commercial priorities include sustaining CF market leadership (IP to 2037), building Casgevy into a blockbuster after >$100 M in 2025 revenue, tripling Jurnavix prescriptions in 2026, and preparing for the U.S. launch of Povy in IgAN.
- The R&D pipeline spans >10 disease areas, highlighted by four mid/late-stage renal programs—Povetacicept (IgAN) and Inaxaplin (AMKD)—each with FDA breakthrough designation and potential accelerated approval.
- Jurnavix achieved 500K scripts in its first year (50% Q4/Q3 growth), secured access for two-thirds of U.S. adults via major PBMs and 900 hospitals, and will expand its field force from 150 to 300 reps to support 3× prescription growth in 2026.
- Vertex guides $11.9–$12.0 B in 2025 revenues, allocates two-thirds of OpEx to innovation, maintains robust operating margins, and leverages a healthy balance sheet for continued R&D and commercialization investments.
Jan 12, 2026, 10:15 PM
Vertex outlines 2026 pipeline and business updates
VRTX
Product Launch
Guidance Update
New Projects/Investments
- CF pipeline acceleration: Vertex plans to submit global approvals for ALYFTREK in children aged 2–5 and initiate a pivotal study in 1–2-year-olds, plus TRIKAFTA filings in one- to two-year-olds in H1 2026; next-generation CFTR correctors VX-828 and VX-581 and CFTR mRNA candidate VX-522 are on track for data readouts in H2 2026.
- CASGEVY momentum: The gene-editing therapy achieved >$100 million in 2025 revenue, treated 60+ patients, presented pediatric SCD/TDT data, and will begin global regulatory submissions in H1 2026, targeting significant growth.
- JOURNAVX uptake: Since FDA approval, 500,000+ prescriptions were filled in 2025, coverage now spans two-thirds of U.S. covered lives (200 million+ individuals); Vertex expects prescriptions to more than triple in 2026 and will file in Canada in H1 2026.
- Renal franchise progress: Rolling BLA filing for povetacicept in IgAN began in Q4 2025 with completion due H1 2026 under priority review; OLYMPUS Phase 2/3 in pMN continues enrollment and a Phase 2 gMG study is set to start in H1 2026.
Jan 11, 2026, 10:00 PM
Vertex outlines 2025 pipeline, commercial progress, and capital allocation at Citi Healthcare Conference
VRTX
M&A
Share Buyback
- Clinical pipeline: Phase 3 trials in diabetic peripheral neuropathy (DPN) enrolling two studies on track for completion in 2026, targeting ~2 million U.S. DPN patients; pipeline includes approved NaV1.8 inhibitor suzetrigine and preclinical NaV1.7 program.
- Renal franchise: Alpine acquisition closed ~18 months ago with rapid integration; RAINIER trial for povetacicept enrolling quickly, interim analysis and rolling submission planned; programs in IgAN, PMN, warm AI hemolytic anemia, and GMG.
- Commercial performance: $500 million revenue reported for vanzacaftor/tezacaftor/deutivacaftor in first nine months, with six-month liver monitoring label requirement; Casgevy on track for >$100 million in 2025 revenue with broad access in U.S., Middle East, and Europe.
- Capital allocation: Repurchased $2 billion of shares in 2025; maintains flexibility for high-science BD and internal investment; Alpine deal cited as ideal size and stage.
Dec 3, 2025, 2:00 PM
Vertex discusses FY 2025 pipeline and commercial updates
VRTX
- Diabetic peripheral neuropathy (DPN) Phase 3 enrollment is on track to complete in 2026, targeting 2 million U.S. patients with high unmet need.
- ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) achieved $500 million in revenues in its first nine months, with steady uptake among naïve and TRIKAFTA-experienced patients and strong FEV₁ and sweat chloride improvements.
- Renal portfolio expansion: POVI engineered for optimal potency, affinity and tissue distribution; poised for monthly subcutaneous auto-injector launch; exploring indications in IgA nephropathy, membranous nephropathy, warm autoimmune hemolytic anemia, GMG and Sjögren’s.
- APOL1-mediated kidney disease Phase 3 interim cohort enrolled; interim data showed a 47.6% proteinuria reduction at 13 weeks in FSGS patients; full readout expected late 2026.
- Casgevy CAR-T ramp: projected >$100 million revenue in 2025; broad access and reimbursement in the U.S., Middle East and Europe; growing patient funnel for 2026 infusions.
Dec 3, 2025, 2:00 PM
Vertex reviews CF product launches and late-stage pipeline at UBS Healthcare Conference 2025
VRTX
Product Launch
- Alyftrek CFTR modulator uptake strongest in treatment-naïve and new-mutation CF patients; U.S. approval in December 2024, EU approval in late 2025, with unchanged monthly-to-annual liver monitoring ex-U.S.
- Povetacicept (Tovy) in IgA nephropathy: Phase III enrollment of >600 patients complete, breakthrough designation secured, rolling BLA to use priority review voucher, with data expected in H1 2026
- Enaxaplin (VX-147) for APOL1-mediated kidney disease: interim Phase III cohort enrolled under FDA accelerated approval agreement; top-line readout anticipated in 2026
- Suzetrigine acute pain launch: surpassed 300,000 scripts by mid-October 2025; coverage for 170 million lives secured across major PBMs and government plans; patient support program ensures no-cost access pre-reimbursement
- Allogeneic stem cell therapy for Type 1 diabetes: pivotal Phase III enrollment complete, dosing paused pending manufacturing analysis, with results to preserve trial integrity
Nov 11, 2025, 3:15 PM
Editas Medicine reports Q3 2025 results and business updates
VRTX
Earnings
Guidance Update
New Projects/Investments
- Editas presented in vivo preclinical proof-of-concept data showing >90% LDL-C reduction in non-human primates within 48 hours of a single EDIT-401 dose; the company plans to file an IND/CTA by mid-2026 and target initial human PoC by year-end 2026.
- Cash, cash equivalents, and marketable securities totaled $165.6 M as of September 30, 2025, and with $17.3 M of subsequent ATM proceeds, the runway is extended into Q3 2027.
- For Q3 2025, net loss was $25.1 M (-$0.28 per share) versus $62.1 M (-$0.75) in Q3 2024; collaboration and other R&D revenues rose to $7.5 M from $0.1 M, R&D expenses fell to $19.8 M from $47.6 M, and G&A expenses declined to $12.3 M from $18.1 M**.
- Editas raised $17.8 M of gross equity proceeds from its ATM facility during Q3 2025 and remains on track for disciplined spending and pipeline advancement.
Nov 10, 2025, 12:00 PM
CRISPR Therapeutics reports positive Phase 1 CTX310 data
VRTX
- Single-course IV CTX310 achieved dose-dependent, durable ANGPTL3 editing with a mean reduction of –73% (max –89%), driving mean –55% triglycerides and –49% LDL at Day 60 at the highest dose.
- In participants with baseline triglycerides >150 mg/dL, CTX310 delivered a 60% mean TG reduction at therapeutic dose levels.
- The therapy was generally well tolerated in 15 participants (0.1–0.8 mg/kg), with no treatment-related serious adverse events or ≥Grade 3 liver transaminase elevations.
- CRISPR is advancing CTX310 into Phase 1b trials in severe hypertriglyceridemia and mixed dyslipidemia to further assess safety and efficacy.
Nov 8, 2025, 2:56 PM
Quarterly earnings call transcripts for VERTEX PHARMACEUTICALS INC / MA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more